Stock Events

Stock Events

Esperion Therapeutics 

€2.76
92
+€0.03+0.99% Friday 06:01

Statistics

Day High
0
Day Low
0
52W High
3.42
52W Low
1.004
Volume
0
Avg. Volume
353
Mkt Cap
712.01M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

4AugExpected
Q1 2026
Q2 2026
-0.08
-0.06
-0.03
-0
Expected EPS
-0.0012554622399999998
Actual EPS
N/A

Financials

-6.38%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
347.92MRevenue
-22.18MNet Income

Analyst Ratings

3.10Average Price Target
The highest estimate is 3.79.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap233.78B
Amgen produces Repatha, a PCSK9 inhibitor that competes directly with Esperion's cholesterol-lowering drugs.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, in collaboration with Sanofi, markets Praluent, another PCSK9 inhibitor, directly competing in the cholesterol management market.
Sanofi
SNY
Mkt Cap107.39B
Sanofi, partnering with Regeneron, is involved in the marketing of Praluent, making it a direct competitor in the cholesterol-lowering space.
Merck
MRK
Mkt Cap366B
Merck & Co. offers cholesterol management drugs that, while not PCSK9 inhibitors, still compete in the broader market for cholesterol treatment solutions.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca provides Crestor, a statin, which is part of the broader cholesterol management market, competing for similar patient populations.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is known for its Lipitor, one of the best-selling cholesterol-lowering drugs, competing in the same therapeutic area.
Novartis
NVS
Mkt Cap292.35B
Novartis has a portfolio of cardiovascular drugs that, while not directly competing as PCSK9 inhibitors, still vie for market share in the broader cardiovascular treatment space.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, through its acquisition of Allergan, has expanded its portfolio into cardiovascular diseases, indirectly competing with Esperion.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline offers a range of cardiovascular drugs, competing in the broader market for heart disease treatments.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company, while not a direct competitor in the PCSK9 space, has a growing interest in cardiovascular diseases, potentially competing for the same patient demographic.

About

Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
Show more...
CEO
ISIN
US29664W1053
WKN
000A1W1SJ

Listings

MU
DE
0ET.MU
BOATS
BOATS
ESPR.BOATS

0 Comments

Share your thoughts

FAQ

What is Esperion Therapeutics stock price today?▼
The current price of 0ET.MU is €2.76 EUR — it has increased by +0.99% in the past 24 hours. Watch Esperion Therapeutics stock price performance more closely on the chart.
What is Esperion Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Esperion Therapeutics stocks are traded under the ticker 0ET.MU.
Is Esperion Therapeutics stock price growing?▼
0ET.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Esperion Therapeutics has showed a +36.71% increase.
What is Esperion Therapeutics market cap?▼
Today Esperion Therapeutics has the market capitalization of 712.01M
What is Esperion Therapeutics revenue for the last year?▼
Esperion Therapeutics revenue for the last year amounts to 347.92M EUR.
What is Esperion Therapeutics net income for the last year?▼
0ET.MU net income for the last year is -22.18M EUR.
In which sector is Esperion Therapeutics located?▼
Esperion Therapeutics operates in the Other sector.
When did Esperion Therapeutics complete a stock split?▼
The last stock split for Esperion Therapeutics was on June 11, 2013 with a ratio of 1:7.